Basilea Launches Another Phase III Trial For Isavuconazole
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With Phase III trials already under way to test isavuconazole as first-line treatment in invasive yeast and mold infections, Basilea Pharmaceutica announced April 15 it has launched an additional study to provide complementary data for its marketing application